Evidence map›Paper›PMID 34805167›Full record

ReviewFrontiers in cell and developmental biology2021

Context Matters-Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer.

Sushmitha Sankarasubramanian, Ulrike Pfohl, Christian R A Regenbrecht, Christoph Reinhard, Lena Wedeken

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Engineering Heterogeneous Tumor Models for Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Sushmitha SankarasubramanianCELLphenomics GmbH, Berlin, Germany.
Ulrike PfohlCELLphenomics GmbH, Berlin, Germany.
Christian R A RegenbrechtCELLphenomics GmbH, Berlin, Germany.
Christoph ReinhardCELLphenomics GmbH, Berlin, Germany.
Lena WedekenCELLphenomics GmbH, Berlin, Germany.
Goethe University Frankfurt · DEUniversitätsklinikum Erlangen · DEUniversitätsmedizin Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is one of the deadliest cancers and remains a major unsolved health problem. While pancreatic ductal adenocarcinoma (PDAC) is associated with driver mutations in only four major genes (

Indexed as

3D cell culture modelscombined targeted and phenotypic approachKRASpancreatic ductal adenocarcinoma (PDAC)patient-derived tumor organoidspersonalized medicinereverse clinical engineeringtumor heterogeneity

Identifiers

PMID34805167
PMCPMC8599957
OpenAlexW3212872546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.